vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and Algorhythm Holdings, Inc. (RIME). Click either name above to swap in a different company.
Algorhythm Holdings, Inc. runs the higher net margin — 169.1% vs -961352.9%, a 961522.0% gap on every dollar of revenue.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Algorhythm Holdings, Inc. is a technology firm that develops AI-powered clinical decision support solutions for the healthcare industry. It primarily caters to healthcare providers across North America, with tools aimed at improving patient care quality, streamlining clinical workflows, and cutting operational costs for medical institutions.
IVA vs RIME — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $-2.1M |
| Net Profit | $-49.0M | $-3.5M |
| Gross Margin | — | 117.3% |
| Operating Margin | — | 135.4% |
| Net Margin | -961352.9% | 169.1% |
| Revenue YoY | — | 56.1% |
| Net Profit YoY | — | 78.2% |
| EPS (diluted) | — | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $-2.1M | ||
| Q2 25 | — | $2.7M | ||
| Q4 24 | — | $-4.7M | ||
| Q2 24 | $5.1K | $2.4M | ||
| Q1 24 | — | $2.4M | ||
| Q3 23 | — | $15.9M | ||
| Q2 23 | — | $2.6M | ||
| Q4 22 | — | $7.1M |
| Q4 25 | — | $-3.5M | ||
| Q2 25 | — | $-809.0K | ||
| Q4 24 | — | $-16.0M | ||
| Q2 24 | $-49.0M | $-6.1M | ||
| Q1 24 | — | $-2.4M | ||
| Q3 23 | — | $97.5K | ||
| Q2 23 | — | $-2.5M | ||
| Q4 22 | — | $-1.9M |
| Q4 25 | — | 117.3% | ||
| Q2 25 | — | 35.1% | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 20.7% | ||
| Q3 23 | — | 23.4% | ||
| Q2 23 | — | 20.2% | ||
| Q4 22 | — | 18.1% |
| Q4 25 | — | 135.4% | ||
| Q2 25 | — | -28.8% | ||
| Q4 24 | — | — | ||
| Q2 24 | — | -252.2% | ||
| Q1 24 | — | -94.3% | ||
| Q3 23 | — | 0.7% | ||
| Q2 23 | — | -92.6% | ||
| Q4 22 | — | -32.1% |
| Q4 25 | — | 169.1% | ||
| Q2 25 | — | -29.8% | ||
| Q4 24 | — | 340.0% | ||
| Q2 24 | -961352.9% | -250.8% | ||
| Q1 24 | — | -97.6% | ||
| Q3 23 | — | 0.6% | ||
| Q2 23 | — | -93.7% | ||
| Q4 22 | — | -27.2% |
| Q4 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.24 | ||
| Q4 24 | — | $-89.56 | ||
| Q2 24 | — | $-190.68 | ||
| Q1 24 | — | $-73.76 | ||
| Q3 23 | — | $0.03 | ||
| Q2 23 | — | $-0.64 | ||
| Q4 22 | — | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-85.4M | $-1.9M |
| Total Assets | $42.6M | $12.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $11.0M | $1.2M | ||
| Q1 24 | — | $4.1M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $1.9M | ||
| Q4 22 | — | $2.8M |
| Q4 25 | — | $-1.9M | ||
| Q2 25 | — | $2.8M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 24 | $-85.4M | $-872.0K | ||
| Q1 24 | — | $5.2M | ||
| Q3 23 | — | $9.7M | ||
| Q2 23 | — | $9.5M | ||
| Q4 22 | — | $13.2M |
| Q4 25 | — | $12.7M | ||
| Q2 25 | — | $12.7M | ||
| Q4 24 | — | $18.3M | ||
| Q2 24 | $42.6M | $12.4M | ||
| Q1 24 | — | $19.9M | ||
| Q3 23 | — | $32.6M | ||
| Q2 23 | — | $15.0M | ||
| Q4 22 | — | $24.2M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
